BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $42.11M (cash outflow) rose 8539.0% year over year, ahead of the +1029.3% change in trailing-twelve-month net income. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +3264.4% a year.

Context

  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$69.83M (-47.9%) for the fiscal year ending Dec 2026, a step up from the -1863.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$42.11M+8.5% QoQ
Last fiscal yearDec 2025
-$134.04M-1863.9% YoY
LTMMar 2026
-$154.1M+1029.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8539.0%-40.6%-8579.7 pp
1 year-1863.9%-47.9%+1815.9 pp
3-year CAGR+3264.4%-20.9%-3285.3 pp
5-year CAGR-19.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(134.04M) USD
Year-over-year change
-1863.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1029.3% is the highest of 10, against a peer median of -3.8%.
  • Over three fiscal years its annual growth of +3264.4% compares with a peer median of +12.7%.
BBOT Competitors
Net Income for BBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M USD+220.5%+13.6%42.0%
KODKodiak Sciences Inc.LTM Sep 2026$246.76M USD+13.5%-11.7%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$208M USD+106.9%-2.1%—
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$157.3M USD-54.5%+3.8%76.8%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$154.1M USD+1029.3%+3264.4%—
URGNUroGen Pharma Ltd.LTM Mar 2026$133.23M USD-3.8%+11.8%94.8%
OCSOculis Holding AGLTM Mar 2026CHF 94.54M CHF-8.3%+34.7%18758.0%
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
SEPNSepterna, Inc.LTM Sep 2026$59M USD+0.3%+20.9%61.3%
ANABAnaptysBio, Inc.LTM Mar 2026$26.79M USD-81.0%—11.5%
Peer median (excluding BBOT) —-3.8%+12.7%67.8%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(74)(3.52K)(41.69K)7.6M(134.04M)
Depreciation & Amortization0000610K
Deferred Income Tax00000
Stock-Based Compensation000271.57K5.87M
Change in Working Capital0015K(104.61K)6.43M
Accounts Receivables00000
Inventory00000
Accounts Payables000172.52K(1.84M)
Other Working Capital0015K(277.13K)8.27M
Other Non-Cash Items743.52K26.69K(8.53M)7.23M
Operating Cash Flow00(52.08M)(763.82K)(113.89M)
Capital Expenditures0000(606K)
Acquisitions (Net)00000
Purchases of Investments000(184M)(83.93M)
Sales of Investments0000157.86M
Other Investing Activities00000
Investing Cash Flow000(184M)73.33M
Debt Repayment000(209.85K)0
Common Stock Issued000187.25M395.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000(578.55K)(12.32M)
Financing Cash Flow000186.46M383.4M
Effect of Forex Changes00000
Net Change in Cash00225K1.7M342.84M
Free Cash Flow00(52.49M)(763.82K)(114.5M)

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.